AKT1 and leukemia: The results showed that PD17 and LY treatment, not PD98 treatment, significantly reduced the percentage of CD117-positive leukemia cells in MA-KO cells compared to MA-WT cells (Figure 4A), suggesting FGFR1 may promote CD117-positive leukemia cells by AKT signaling.